Kojarunchitt Thunjiradasiree, Baldursdottir Stefania, Dong Yao-Da, Boyd Ben J, Rades Thomas, Hook Sarah
School of Pharmacy, University of Otago, Dunedin, New Zealand.
Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark.
Eur J Pharm Biopharm. 2015 Jan;89:74-81. doi: 10.1016/j.ejpb.2014.11.026. Epub 2014 Dec 3.
Thermoresponsive, particle-loaded, Poloxamer 407 (P407)-Pluronic-R® (25R4) or chitosan-methyl cellulose (MC) formulations were developed as single-dose, sustained release vaccines. The sol-gels, loaded either with a particulate vaccine (cubosomes) or soluble antigen (ovalbumin) and adjuvants (Quil A and monophosphoryl lipid A), were free-flowing liquids at room temperature and formed stable gels at physiological temperatures. Rheological results showed that both systems meet the criteria of being thermoresponsive gels. The P407-25R4 sol-gels did not significantly sustain the release of antigen in vivo while the chitosan-MC sol-gels sustained the release of antigen up to at least 14 days after administration. The chitosan-MC sol-gels stimulated both cellular and humoral responses. The inclusion of cubosomes in the sol-gels did not provide a definitive beneficial effect. Further analysis of the formulations with small-angle X-ray scattering (SAXS) revealed that while cubosomes were stable in chitosan-MC gels they were not stable in P407-25R4 formulations. The reason for the mixed response to cubosome-loaded vehicles requires more investigation, however it appears that the cubosomes did not facilitate synchronous vaccine release and may in fact retard release, reducing efficacy in some cases. From these results, chitosan-MC sol-gels show potential as sustained release vaccine delivery systems, as compared to the P407-25R4 system that had a limited ability to sustain antigen release.
开发了热敏性、负载颗粒的泊洛沙姆407(P407)-普朗尼克-R®(25R4)或壳聚糖-甲基纤维素(MC)制剂作为单剂量缓释疫苗。这些溶胶-凝胶负载了颗粒疫苗(立方液晶纳米粒)或可溶性抗原(卵清蛋白)以及佐剂(Quil A和单磷酰脂质A),在室温下为自由流动的液体,在生理温度下形成稳定的凝胶。流变学结果表明,这两种体系均符合热敏性凝胶的标准。P407-25R4溶胶-凝胶在体内不能显著维持抗原释放,而壳聚糖-MC溶胶-凝胶在给药后至少14天内持续释放抗原。壳聚糖-MC溶胶-凝胶刺激了细胞和体液反应。在溶胶-凝胶中加入立方液晶纳米粒并未产生明确的有益效果。用小角X射线散射(SAXS)对制剂进行的进一步分析表明,虽然立方液晶纳米粒在壳聚糖-MC凝胶中稳定,但在P407-25R4制剂中不稳定。对负载立方液晶纳米粒载体的混合反应原因需要更多研究,然而,立方液晶纳米粒似乎并未促进疫苗同步释放,实际上可能会延迟释放,在某些情况下降低疗效。从这些结果来看,与抗原释放能力有限的P407-25R4系统相比,壳聚糖-MC溶胶-凝胶显示出作为缓释疫苗递送系统的潜力。
J Pharm Pharmacol. 2008-12
Adv Healthc Mater. 2023-7
Vaccines (Basel). 2022-11-11
Colloids Surf A Physicochem Eng Asp. 2022-4-5
Adv Ther (Weinh). 2020-11